Merck & Co., Inc.
Merck Reports First-Quarter 2026 Financial Results and Highlights Regulatory Approvals
Summary
Merck & Co., Inc. reported first-quarter 2026 financial results, showing total worldwide sales of $16.3 billion, a 5% increase year-over-year. The company reported a GAAP loss per share of $1.72 and a non-GAAP loss per share of $1.28, primarily due to a $3.62 per share charge for the acquisition of Cidara. Key product sales included KEYTRUDA with $8.0 billion, WINREVAIR with $525 million, and Animal Health with $1.8 billion. Merck also announced several regulatory approvals and clinical milestones, including the FDA approval of IDVYNSO for certain adults with virologically suppressed HIV-1 and the EC approval of ENFLONSIA for the prevention of RSV lower respiratory tract disease in infants. The company raised its full-year 2026 financial outlook, expecting sales between $65.8 billion and $67.0 billion and non-GAAP EPS between $5.04 and $5.16.
Profitelligence Alerts
Get alerts for MRK
Be first to know when Merck & Co., Inc. files with the SEC.
Filing Categories
Advertisement
About Merck & Co., Inc.
Merck & Co., Inc. is a prominent player in the global pharmaceutical industry. It is primarily focused on the research, development, production, and marketing of drugs and vaccines. Known for its strong emphasis on innovative health solutions, Merck develops treatments and vaccines for a variety of diseases affecting humans and animals. Key areas include oncology, infectious diseases, diabetes, and vaccines, reflecting its commitment to addressing critical health challenges worldwide. The company operates in several strategic regions, exporting its advanced therapies to meet healthcare needs across different markets. With a robust pipeline of new products and significant investment in research and development, Merck plays a vital role in advancing medical breakthroughs and enhancing patient care. Beyond pharmaceuticals, Merck is involved in animal health, providing veterinary vaccines and services, contributing to agricultural productivity and food security. The company's ongoing efforts in groundbreaking research and public health initiatives underscore its importance in the healthcare sector.
Official SEC Documents
Advertisement